Akeso’s ivonescimab posts 14.9-month median OS vs. 12.1 for Imfinzi in China Ph3 biliary tract cancer trial at ESMO.
MADRID — AstraZeneca said Sunday it might have found a way for patients with mutant non-small cell lung cancer to keep ...
Pfizer’s failed Seagen ADC sigvotatug vedotin showed a 2.5-month OS edge in second-line NSCLC in a post-hoc ESMO analysis.
Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Editor’s note: Longtime oncology R&D expert ...
Arsalan Arif is the founder and CEO of Endpoints News. Since launching the company in 2016 with John Carroll, Arsalan built Endpoints into a global newsroom of more than 70 journalists and media ...
Bristol Myers’ cell therapy chief Lynelle Hoch explains the reagent behind its autoimmune CAR-T pause and a puzzling MS trial ...
Roivant's brepocitinib (Lisraya) succeeded in two non-infectious uveitis trials, with plans to file for approval in H1 2027.
Gilead pays $1.28B upfront to China's PepStar Therapeutics for oral IL-23 inhibitor HCXT-2001, targeting IBD and psoriasis, ...
Treasury’s draft outbound investment rules would sharply limit US deals for Chinese drug and biotech assets, opening a 45-day ...
Basel-based Windward Bio filed for Nasdaq IPO as $WWB, advancing WIN378 and WIN027 from Kelun-Biotech, Harbour BioMed, and Qyuns for asthma, COPD, and eczema.
Redesign Health merges with Sheba Medical Center’s ARC Global in a roughly $2B deal and plans to acquire advisory firm AVIA.
Roche touts 88% Phase 3 success rate as it culls afimkibart’s AD trial and seven early assets ahead of giredestrant launch.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results